BR9908722A - Uso de derivados de ácido fumárico na medicina de transplante - Google Patents

Uso de derivados de ácido fumárico na medicina de transplante

Info

Publication number
BR9908722A
BR9908722A BR9908722-7A BR9908722A BR9908722A BR 9908722 A BR9908722 A BR 9908722A BR 9908722 A BR9908722 A BR 9908722A BR 9908722 A BR9908722 A BR 9908722A
Authority
BR
Brazil
Prior art keywords
fumaric acid
acid derivatives
medicine
transplant medicine
transplant
Prior art date
Application number
BR9908722-7A
Other languages
English (en)
Inventor
Kumar Rajendra Joshi
Hans-Peter Strebel
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of BR9908722A publication Critical patent/BR9908722A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Patente de Invenção: <B>''USO DE DERIVADOS DE áCIDO FUMáRICO NA MEDICINA DE TRANSPLANTE''<D>. A invenção refere-se ao uso de certos ésteres monoalquílicos de ácido fumárico como sais ou um ácido livre ou sozinho ou em combinação com um fumarato de dialquila, para a produção de preparações farmacêuticas para uso na medicina de transplante, especialmente para o tratamento, alívio ou supressão das reações de hospedeiro versus tecido transplantado. Para este propósito, os ésteres monoalquílicos de ácido fumárico podem ser usados em combinação com as preparações convencionalmente usadas na medicina de transplante e imunossupressivos, especialmente tais como as ciclosporinas.
BR9908722-7A 1998-08-31 1999-08-20 Uso de derivados de ácido fumárico na medicina de transplante BR9908722A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19839566A DE19839566C2 (de) 1998-08-31 1998-08-31 Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
PCT/EP1999/006110 WO2000012072A2 (de) 1998-08-31 1999-08-20 Verwendung von fumarsäurederivaten in der transplantationsmedizin

Publications (1)

Publication Number Publication Date
BR9908722A true BR9908722A (pt) 2001-10-16

Family

ID=7879272

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908722-7A BR9908722A (pt) 1998-08-31 1999-08-20 Uso de derivados de ácido fumárico na medicina de transplante

Country Status (25)

Country Link
US (1) US6359003B1 (pt)
EP (1) EP1107749B1 (pt)
JP (1) JP3553883B2 (pt)
CN (1) CN1195511C (pt)
AT (1) ATE241353T1 (pt)
AU (1) AU746958B2 (pt)
BG (1) BG64435B1 (pt)
BR (1) BR9908722A (pt)
CA (1) CA2322188C (pt)
DE (2) DE19839566C2 (pt)
DK (1) DK1107749T3 (pt)
EE (1) EE05025B1 (pt)
ES (1) ES2195609T3 (pt)
HK (1) HK1040623B (pt)
HU (1) HUP0101854A3 (pt)
IL (1) IL138110A0 (pt)
NO (1) NO20006462L (pt)
NZ (1) NZ506573A (pt)
PL (1) PL198211B1 (pt)
PT (1) PT1107749E (pt)
RS (1) RS49780B (pt)
RU (1) RU2210364C2 (pt)
SK (1) SK286352B6 (pt)
TR (1) TR200002475T2 (pt)
WO (1) WO2000012072A2 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
ATE447945T1 (de) * 2001-01-12 2009-11-15 Biogen Idec Internat Gmbh Verwendung von fumarsäureamiden
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
AU2003236156A1 (en) * 2003-04-24 2005-01-04 Shin-Jen Shiao Pharmaceutical compositions used for immune disease treatment and improvement
SI1663197T1 (sl) 2003-09-09 2008-06-30 Biogen Idec Internat Gmbh Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
PT2801355E (pt) * 2004-10-08 2015-09-18 Forward Pharma As Composições farmacêuticas de libertação controlada compreendendo um éster de ácido fumárico
WO2007006308A1 (en) * 2005-07-07 2007-01-18 Aditech Pharma Ab Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use
WO2007006307A2 (en) * 2005-07-07 2007-01-18 Aditech Pharma Ab Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2007042034A1 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
ES2599227T3 (es) * 2007-02-08 2017-01-31 Biogen Ma Inc. Neuroprotección en enfermedades desmielinizantes
ES2916604T1 (es) 2007-02-08 2022-07-04 Biogen Ma Inc Ensayos de detección de nrf2 y métodos y composiciones relacionados
WO2009078754A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
PL2334378T3 (pl) 2008-08-19 2014-09-30 Xenoport Inc Proleki wodorofumaranu metylu, ich kompozycje farmaceutyczne i sposoby zastosowania
EP2564839B1 (en) 2009-01-09 2016-05-11 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
PL2718257T3 (pl) 2011-06-08 2018-04-30 Biogen Ma Inc. Sposób przygotowywania dimetylofumaranu krystalicznego o wysokiej czystości
CN103826624A (zh) * 2011-08-30 2014-05-28 富山化学工业株式会社 类风湿性关节炎等自身免疫疾病的处置的改善方法
EP2782561A1 (en) 2011-11-24 2014-10-01 Synthon BV Controlled release particles comprising dimethyl fumarate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
CN114146079A (zh) 2012-02-07 2022-03-08 比奥根玛公司 含有富马酸二甲酯的药物组合物
MX2014009511A (es) 2012-02-07 2014-10-24 Xenoport Inc Compuestos de fumarato de morfolinoalquilo, composiciones farmaceuticas y metodos de uso.
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140057918A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
JP2015526477A (ja) 2012-08-22 2015-09-10 ゼノポート，インコーポレイティド メチル水素フマレートの経口剤形およびそのプロドラッグ
CN103483194B (zh) * 2012-11-30 2016-03-09 杨寅柯 一种2-氟代富马酸酯(结构式i)及其制备方法及应用
AR094277A1 (es) 2012-12-21 2015-07-22 Biogen Idec Inc Derivados de fumarato sustituidos con deuterio
SG11201507371RA (en) 2013-03-14 2015-10-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
EA037666B1 (ru) * 2015-02-08 2021-04-28 Алкермес Фарма Айрленд Лимитед Фармацевтическая композиция, содержащая 2-(2,5-диоксопирролидин-1-ил)этилметилфумарат, и ее применение в медицине
WO2016160635A1 (en) 2015-03-27 2016-10-06 Sytheon Limited Compositions and methods for treating psoriasis
WO2017060420A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected fumaric acid-based metabolites for the treatment of autoimmune diseases
CN106265621B (zh) * 2016-09-19 2019-05-17 苏州大学 富马酸二甲酯在制备预防和治疗移植物抗宿主病及移植物抗白血病药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
US5149695A (en) * 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US5424332A (en) * 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US6011000A (en) 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
AU3889197A (en) 1996-07-26 1998-02-20 Douglas V Faller Compositions comprising an inducing agent and an anti-viral agent for the treat ment of blood, viral and cellular disorders
AU5474198A (en) * 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19814358C2 (de) * 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn

Also Published As

Publication number Publication date
HK1040623B (zh) 2005-08-19
HK1040623A1 (en) 2002-06-21
HUP0101854A3 (en) 2003-04-28
HUP0101854A2 (hu) 2001-11-28
PL198211B1 (pl) 2008-06-30
JP3553883B2 (ja) 2004-08-11
SK286352B6 (en) 2008-07-07
EE200000654A (et) 2002-04-15
DE19839566C2 (de) 2002-01-17
US6359003B1 (en) 2002-03-19
DK1107749T3 (da) 2003-08-18
JP2002525276A (ja) 2002-08-13
BG64435B1 (en) 2005-02-28
ES2195609T3 (es) 2003-12-01
NZ506573A (en) 2002-10-25
RU2210364C2 (ru) 2003-08-20
YU58800A (sh) 2002-03-18
WO2000012072A3 (de) 2000-05-04
PL347359A1 (en) 2002-04-08
EP1107749A2 (de) 2001-06-20
NO20006462L (no) 2001-04-30
BG104679A (en) 2001-02-28
AU5737899A (en) 2000-03-21
ATE241353T1 (de) 2003-06-15
CN1316901A (zh) 2001-10-10
CA2322188C (en) 2004-03-09
IL138110A0 (en) 2001-10-31
NO20006462D0 (no) 2000-12-18
EE05025B1 (et) 2008-06-16
WO2000012072A2 (de) 2000-03-09
AU746958B2 (en) 2002-05-09
TR200002475T2 (tr) 2001-03-21
CN1195511C (zh) 2005-04-06
DE19839566A1 (de) 2000-03-09
PT1107749E (pt) 2003-08-29
DE59905763D1 (de) 2003-07-03
SK2572001A3 (en) 2002-05-09
CA2322188A1 (en) 2000-03-09
EP1107749B1 (de) 2003-05-28
RS49780B (sr) 2008-06-05

Similar Documents

Publication Publication Date Title
BR9908722A (pt) Uso de derivados de ácido fumárico na medicina de transplante
ES2269169T3 (es) Esteres de acido hialuronico para el tratamiento de la cicatrizacion normotrofica de la piel.
BR9809655A (pt) Uso de derivados do ácido fumárico
DE59905954D1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
ATE271886T1 (de) Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
DK0418339T3 (da) Præparat og fremgangsmåde til forebyggelse af sammenvoksninger mellem kropsvæv
ATE206058T1 (de) Kunsthaut, enthaltend als träger bioverträgliche materialen aus hyaluronsäurederivaten
ATE217197T1 (de) Verwendung von hyaluronsäure und eines nsaid zur herstellung eines arzneimittels zur behandlung von krankheiten der mucosa
ATE426402T1 (de) Medizinische zusammensetzungen enthaltend 2-amino-2-a2-(4-octylphenyl)ethylupropan-1,3-di l
DE60313356D1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
BR0311371A (pt) Composições para uso terapêutico compreendendo uma vitamina, um sal de metal e insulina ou um hormÈnio de crescimento
ES2191083T3 (es) Composicion para limpiar y/o desinfectar instrumentos para uso medico.
UY26514A1 (es) &#34; composición para el tratamiento de tejidos danados&#34;.
BR9509634A (pt) Solução aquosa concentrada estável ao armazenamento para infusao uso da mesma e processos de preparação da mesma de tratamento de um paciente necessitando de um inibidor de trombina e de estabilização de um inibidor de trombina ativo
Bashford The Coming of Antisepsis.
DE69832796D1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
IKiLLY et al. COUNNCIL. NOTICE OF
Gaw " A time to heal": The diffusion of Listerian doctrine in Victorian Britain.
Tabata Regenerative Medical Therapy for Hard Tissues Based on Tissue Engineering
Boswick The history of burn care in the USA
Brown A Distinctive Colour for Chloroform
US et al. THEIMPACT or sunsm on THE uvlzn
Th et al. HOURS OF ATTENDANCE AND OPERATION DAYS
DE60112253D1 (de) Verwendung von xanthinederivaten zur herstellung eines arzneimittels zur behandlung oder verhütung von osteoporose

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: A61K 31/225, A61P 15/10, A61K 9/16, A61K 9/26

Ipc: A61K 31/225 (2007.10), A61P 15/10 (2007.10), A61K

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.